Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REG1 versus bivalirudin in patients undergoing PCI
2013-001384-23Phase 3Terminated
- Sponsor
- Regado Biosciences
- Start
- Aug 2013
- Modality
- Small Molecules, Peptides, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegnivacogin, Anivamersen and bivalirudin in coronary arteriosclerosis (2 arms), sponsored by Regado Biosciences. Started Aug 2013; status: terminated.
02
Drugs
pegnivacoginAnivamersenbivalirudin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2013-001384-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001384-23.